Literature DB >> 34936238

Guinea Pig and Mouse Models for Genital Herpes Infection.

Lauren M Hook1, Harvey M Friedman1, Sita Awasthi1.   

Abstract

This article describes procedures for two preclinical animal models for genital herpes infection. The guinea pig model shares many features of genital herpes in humans, including a natural route of inoculation, self-limiting primary vulvovaginitis, spontaneous recurrences, symptomatic and subclinical shedding of HSV-2, and latent infection of the associated sensory ganglia (lumbosacral dorsal root ganglia, DRG). Many humoral and cytokine responses to HSV-2 infection in the guinea pig have been characterized; however, due to the limited availability of immunological reagents, assessments of cellular immune responses are lacking. In contrast, the mouse model has been important in assessing cellular immune responses to herpes infection. Both the mouse and guinea pig models have been extremely useful for evaluating preventative and immunotherapeutic approaches for controlling HSV infection and recurrent disease. In this article, we describe procedures for infecting guinea pigs and mice with HSV-2, scoring subsequent genital disease, and measuring replicating virus to confirm infection. We also provide detailed protocols for dissecting and isolating DRG (the site of HSV-2 latency), quantifying HSV-2 genomic copies in DRG, and assessing symptomatic and subclinical shedding of HSV-2 in the vagina.
© 2021 Wiley Periodicals LLC. Basic Protocol 1: Primary and recurrent genital herpes infection in the guinea pig model Support Protocol 1: Blood collection via lateral saphenous vein or by cardiac puncture after euthanasia Support Protocol 2: Dissection and isolation of dorsal root ganglia from guinea pigs Support Protocol 3: PCR amplification and quantification of HSV-2 genomic DNA from samples Basic Protocol 2: Primary genital herpes infection in the mouse model Alternate Protocol: Flank infection with HSV-2 in the mouse model Support Protocol 4: Dissection and isolation of mouse dorsal root ganglia. © 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  HSV-2; HSV-2 shedding; animal models; genital infection; guinea pig model; mouse model; recurrent infection; skin infection

Mesh:

Year:  2021        PMID: 34936238      PMCID: PMC8747063          DOI: 10.1002/cpz1.332

Source DB:  PubMed          Journal:  Curr Protoc        ISSN: 2691-1299


  37 in total

1.  Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Authors:  Sita Awasthi; Elizabeth E Zumbrun; Huaxin Si; Fushan Wang; Carolyn E Shaw; Michael Cai; John M Lubinski; Shana M Barrett; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 2.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

3.  Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.

Authors:  L A Morrison; D M Knipe
Journal:  Virology       Date:  1997-12-22       Impact factor: 3.616

4.  Virologic characteristics of subclinical and symptomatic genital herpes infections.

Authors:  A Wald; J Zeh; S Selke; R L Ashley; L Corey
Journal:  N Engl J Med       Date:  1995-09-21       Impact factor: 91.245

5.  Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2.

Authors:  Amy E Gillgrass; Ali A Ashkar; Kenneth L Rosenthal; Charu Kaushic
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Herpes simplex virus: propagation, quantification, and storage.

Authors:  John A Blaho; Elise R Morton; Jamie C Yedowitz
Journal:  Curr Protoc Microbiol       Date:  2005-10

7.  Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.

Authors:  Christopher Petro; Pablo A González; Natalia Cheshenko; Thomas Jandl; Nazanin Khajoueinejad; Angèle Bénard; Mayami Sengupta; Betsy C Herold; William R Jacobs
Journal:  Elife       Date:  2015-03-10       Impact factor: 8.140

8.  Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.

Authors:  Marie-Clotilde Bernard; Véronique Barban; Fabrine Pradezynski; Aymeric de Montfort; Robert Ryall; Catherine Caillet; Patricia Londono-Hayes
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

9.  Successful application of prime and pull strategy for a therapeutic HSV vaccine.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Sita Awasthi; Peiwen Lu; Derek A Pullum; David A Dixon; Akiko Iwasaki; Harvey M Friedman
Journal:  NPJ Vaccines       Date:  2019-08-01       Impact factor: 7.344

10.  Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2.

Authors:  William P Halford; Joshua Geltz; Ronald J Messer; Kim J Hasenkrug
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.